Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence

Rheumatology International

Volumn 37, Issue 8, 2017, Pages 1249-1255

  Sciascia, Savino ^a   Radin, Massimo ^a   Yazdany, Jinoos ^b   Tektonidou, Maria ^c   Cecchi, Irene ^a   Roccatello, Dario ^a   Dall’Era, Maria ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Antiphospholipid antibodies; Complement; Eculizumab; Lupus nephritis; Systemic lupus erythematosus

Indexed keywords

COMPLEMENT; ECULIZUMAB; MONOCLONAL ANTIBODY; URINARY TRACT AGENT;

ANTIPHOSPHOLIPID SYNDROME; CLINICAL OUTCOME; COCHRANE LIBRARY; DISEASE SEVERITY; DRUG EFFICACY; EMBASE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPOCOMPLEMENTEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDLINE; PRIORITY JOURNAL; REVIEW; SCOPUS; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; ACUTE KIDNEY FAILURE; COMPLICATION; FEMALE; IMMUNOLOGY; KIDNEY; MALE; PATHOLOGY;

ACUTE KIDNEY INJURY; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; KIDNEY; LUPUS NEPHRITIS; MALE; RENAL AGENTS; THROMBOTIC MICROANGIOPATHIES;

EID: 85014182080     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-017-3686-5     Document Type: Review

References (43)

1. Wu H, Zhao M, Tan L, Lu Q (2016) The key culprit in the pathogenesis of systemic lupus erythematosus: aberrant DNA methylation. Autoimmun Rev 15:684–689. doi:10.1016/j.autrev.2016.03.002
2. Lipsky PE (2001) Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2:764–766. doi:10.1038/ni0901-764
3. Mak A, Kow NY (2014) The pathology of T cells in systemic lupus erythematosus. J Immunol Res 2014:419029. doi:10.1155/2014/419029
4. Schneider M (2016) Pitfalls in lupus. Autoimmun Rev. doi:10.1016/j.autrev.2016.07.033
5. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA et al (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349:1526–1533. doi:10.1056/NEJMoa021933
6. Pisetsky DS (2015) Anti-DNA antibodies—quintessential biomarkers of SLE. Nat Rev Rheumatol 12:102–110. doi:10.1038/nrrheum.2015.151
7. Frieri M, Stampfl H (2016) Systemic lupus erythematosus and atherosclerosis: review of the literature. Autoimmun Rev 15:16–21. doi:10.1016/j.autrev.2015.08.007
8. Elkon KB, Santer DM (2012) Complement, interferon and lupus. Curr Opin Immunol 24:665–670. doi:10.1016/j.coi.2012.08.004
9. Carroll MC (2000) A protective role for innate immunity in autoimmune disease. Clin Immunol 95:S30–S38. doi:10.1006/clim.1999.4813
10. Kaya Z, Afanasyeva M, Wang Y, Dohmen KM, Schlichting J, Tretter T et al (2001) Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nat Immunol 2:739–745. doi:10.1038/90686
11. Fleming SD, Shea-Donohue T, Guthridge JM, Kulik L, Waldschmidt TJ, Gipson MG et al (2002) Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J Immunol 169:2126–2133
12. Carroll MC (2000) The role of complement in B cell activation and tolerance. Adv Immunol 74:61–88
13. Barilla-LaBarca ML, Toder K, Furie R (2013) Targeting the complement system in systemic lupus erythematosus and other diseases. Clin Immunol 148:313–321. doi:10.1016/j.clim.2013.02.014
14. Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA (1996) Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA 93:8563–8568
15. Belot A, Cimaz R (2012) Monogenic forms of systemic lupus erythematosus: new insights into SLE pathogenesis. Pediatr Rheumatol Online J 10:21. doi:10.1186/1546-0096-10-21
16. Lee YH, Witte T, Momot T, Schmidt RE, Kaufman KM, Harley JB et al (2005) The mannose-binding lectin gene polymorphisms and systemic lupus erythematosus: two case-control studies and a meta-analysis. Arthritis Rheum 52:3966–3974. doi:10.1002/art.21484
17. Jönsen A, Nilsson SC, Ahlqvist E, Svenungsson E, Gunnarsson I, Eriksson KG et al (2011) Mutations in genes encoding complement inhibitors CD46 and CFH affect the age at nephritis onset in patients with systemic lupus erythematosus. Arthritis Res Ther 13:R206. doi:10.1186/ar3539
18. Hillmen P, Hall C, Marsh JCW, Elebute M, Bombara MP, Petro BE et al (2004) Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 350:552–559. doi:10.1056/NEJMoa031688
19. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C et al (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169–2181. doi:10.1056/NEJMoa1208981
20. Oku K, Nakamura H, Kono M, Ohmura K, Kato M, Bohgaki T et al (2016) Complement and thrombosis in the antiphospholipid syndrome. Autoimmun Rev. doi:10.1016/j.autrev.2016.07.020
21. Huda R, Tüzün E, Christadoss P (2014) Targeting complement system to treat myasthenia gravis. Rev Neurosci 25:575–583. doi:10.1515/revneuro-2014-0021
22. Reis ES, Mastellos DC, Yancopoulou D, Risitano AM, Ricklin D, Lambris JD (2015) Applying complement therapeutics to rare diseases. Clin Immunol 161:225–240. doi:10.1016/j.clim.2015.08.009
23. Kessler RA, Mealy MA, Levy M (2016) Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic. Curr Treat Options Neurol 18:2. doi:10.1007/s11940-015-0387-9
24. Shapiro R, Chin-Yee I, Lam S (2015) Eculizumab as a bridge to immunosuppressive therapy in severe cold agglutinin disease of anti-Pr specificity. Clin Case Reports 3:942–944. doi:10.1002/ccr3.399
25. Manrique J, Cravedi P (2014) Role of monoclonal antibodies in the treatment of immune-mediated glomerular diseases. Nefrol Publicación Of La Soc Española Nefrol 34:388–397. doi:10.3265/Nefrologia.pre2014.Feb.12506
26. Lonze BE, Singer AL, Montgomery RA (2010) Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 362:1744–1745. doi:10.1056/NEJMc0910965
27. Vivarelli M, Pasini A, Emma F (2012) Eculizumab for the treatment of dense-deposit disease. N Engl J Med 366:1163–1165. doi:10.1056/NEJMc1111953
28. Kulkarni S, Kirkiles-Smith NC, Deng YH, Formica RN, Moeckel G, Broecker V et al (2016) Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: a pilot, randomized-controlled trial. Am J Transplant. doi:10.1111/ajt.14001
29. Coppo R, Peruzzi L, Amore A, Martino S, Vergano L, Lastauka I et al (2015) Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol 30:167–172. doi:10.1007/s00467-014-2944-y
30. El-Husseini A, Hannan S, Awad A, Jennings S, Cornea V, Sawaya BP (2014) Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis 65:127–130. doi:10.1053/j.ajkd.2014.07.031
31. Boneparth A, Moorthy LN, Weiss L, Rajasekhar H, Murphy S, Drachtman RA (2015) Complement inhibition in the treatment of SLE-associated thrombotic thrombocytopenic purpura. Glob Pediatr Heal 2:2015–2017. doi:10.1177/2333794X15570150
32. Hadaya K, Ferrari-Lacraz S, Fumeaux D, Boehlen F, Toso C, Moll S et al (2011) Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant 11:2523–2527. doi:10.1111/j.1600-6143.2011.03696.x
33. Kronbichler A, Frank R, Kirschfink M, Szilágyi Á, Csuka D, Prohászka Z et al (2014) Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine (Baltimore) 93:e143. doi:10.1097/MD.0000000000000143
34. Pickering MC, Ismajli M, Condon MB, McKenna N, Hall AE, Lightstone L et al (2015) Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatol (United Kingdom) 54:2286–2288. doi:10.1093/rheumatology/kev307
35. Tektonidou MG, Sotsiou F, Moutsopoulos HM (2008) Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS. J Rheumatol 35:1983–1988
36. Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM (2004) Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum 50:2569–2579. doi:10.1002/art.20433
37. Canaud G, Kamar N, Anglicheau D, Esposito L, Rabant M, Noël L-H et al (2013) Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant 13:2179–2185. doi:10.1111/ajt.12319
38. Sciascia S, Cuadrado MJ, Khamashta M, Roccatello D (2014) Renal involvement in antiphospholipid syndrome. Nat Rev Nephrol 10:279–289. doi:10.1038/nrneph.2014.38
39. Miyasaka N, Miura O, Kawaguchi T, Arima N, Morishita E, Usuki K et al (2016) Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review. Int J Hematol 103:703–712. doi:10.1007/s12185-016-1946-x
40. De Sousa Amorim E, Blasco M, Quintana L, Sole M, de Cordoba SR, Campistol JM (2015) Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: insights for optimizing management. J Nephrol 28:641–645. doi:10.1007/s40620-015-0173-5
41. Sciascia S, Baldovino S, Schreiber K, Solfietti L, Roccatello D (2015) Antiphospholipid Syndrome and the Kidney. Semin Nephrol 35:478–486. doi:10.1016/j.semnephrol.2015.08.009
42. Moroni G, Doria A, Giglio E et al (2016) Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study. J Autoimmun 74:194–200. doi:10.1016/j.jaut.2016.06.012
43. Furie R, Matis L, Rollins S et al (2004) A single dose, placebocontrolled, double blind, phase I study of the humanized anti-C5 antibody h5G1.1 in patients with systemic lupus erythematosus. Arthritis Rheum 50:S35–S747